Arbutus Biopharma Statistics

Total Valuation

LON:0SGC has a market cap or net worth of GBP 604.51 million. The enterprise value is 535.44 million.

Market Cap	604.51M
Enterprise Value	535.44M

Important Dates

The next estimated earnings date is Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	189.49M
Shares Outstanding	n/a
Shares Change (YoY)	+8.75%
Shares Change (QoQ)	+0.89%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	126.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	53.72
PB Ratio	9.98
P/TBV Ratio	9.98
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-13.52
EV / Sales	46.81
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-12.17

Financial Position

The company has a current ratio of 20.53, with a Debt / Equity ratio of 0.06.

Current Ratio	20.53
Quick Ratio	19.76
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-384.81

Financial Efficiency

Return on equity (ROE) is -52.82% and return on invested capital (ROIC) is -25.39%.

Return on Equity (ROE)	-52.82%
Return on Assets (ROA)	-21.01%
Return on Invested Capital (ROIC)	-25.39%
Return on Capital Employed (ROCE)	-45.04%
Revenue Per Employee	255,730
Profits Per Employee	-899,967
Employee Count	44
Asset Turnover	0.12
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +35.03% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+35.03%
50-Day Moving Average	3.39
200-Day Moving Average	3.46
Relative Strength Index (RSI)	49.03
Average Volume (20 Days)	1,640

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.84

Income Statement

In the last 12 months, LON:0SGC had revenue of GBP 11.25 million and -39.60 million in losses. Loss per share was -0.21.

Revenue	11.25M
Gross Profit	-27.29M
Operating Income	-32.30M
Pretax Income	-39.60M
Net Income	-39.60M
EBITDA	-31.56M
EBIT	-32.30M
Loss Per Share	-0.21

Full Income Statement

Balance Sheet

The company has 71.59 million in cash and 3.65 million in debt, giving a net cash position of 67.95 million.

Cash & Cash Equivalents	71.59M
Total Debt	3.65M
Net Cash	67.95M
Net Cash Per Share	n/a
Equity (Book Value)	60.56M
Book Value Per Share	0.32
Working Capital	71.60M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -43.93 million and capital expenditures -62,771, giving a free cash flow of -44.00 million.

Operating Cash Flow	-43.93M
Capital Expenditures	-62,771
Free Cash Flow	-44.00M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	-242.54%
Operating Margin	-287.06%
Pretax Margin	-351.92%
Profit Margin	n/a
EBITDA Margin	-280.51%
EBIT Margin	-287.06%
FCF Margin	n/a

Dividends & Yields

LON:0SGC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.75%
Shareholder Yield	-8.75%
Earnings Yield	-6.55%
FCF Yield	-7.28%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0SGC has an Altman Z-Score of 1.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.22
Piotroski F-Score	4